TuHURA Biosciences (HURA) stock rises following FDA hold lift

Investing.com -- TuHURA Biosciences Inc (NASDAQ: HURA) shares climbed 5% today after the U.S. Food and Drug Administration (FDA) lifted a manufacturing-related partial clinical hold on the company's Phase 3 trial for its cancer treatment, IFx-2.0. This move allows the trial to proceed under the Special Protocol Assessment (SPA) Agreement previously established with the FDA.

The clinical hold's removal has been positively received by the market as it signals a step forward for TuHURA's IFx-2.0, which is being developed as an adjunctive therapy in combination with Keytruda® for the treatment of advanced or metastatic Merkel Cell Carcinoma (MCC). The trial is set to enroll 118 patients across 22 to 25 U.S. sites.

James Bianco, M.D., President and CEO of TuHURA Biosciences, expressed gratitude for the FDA's quick response and useful recommendations, which have led to the resumption of the trial. Dr. Bianco also highlighted the financial benefit of the hold's removal, triggering an additional $2.23 million payment to the company under a recent private placement agreement.

The pivotal trial aims to demonstrate the efficacy of IFx-2.0 in improving Overall Response Rate (ORR) and Progression Free Survival (PFS) when used with Keytruda®, compared to Keytruda® plus placebo. Successful achievement of the ORR primary endpoint could lead to accelerated approval, and a positive PFS result may satisfy the requirements for regular approval, potentially without the need for a post-approval confirmatory trial.

Investors appear to be optimistic about TuHURA's progress, as reflected in the stock's performance today. The company's ability to move forward with its Phase 3 trial is a significant milestone in the development of IFx-2.0 and could have important implications for patients with MCC.

You May Also Be Interested In

• AAR To Pay $1.8B For Stake In Aircraft-maintenance Company - WSJ
• U.S. Army awards Navitas a contract for 10 kV SiC semiconductors
• Trane Technologies adds two 250 MW AI factory cooling designs